Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018; 10(1): 31-39 [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31]
Corresponding Author of This Article
Xiao-Tian Zhang, MD, Professor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. zhangxiaotianmed@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 2 Multivariate analysis of the prognostic factors for overall survival of T4bN1-3M0/TxN3bM0 gastric cancer patients
Clinicopathological characteristics
P value
Odds ratio
95%CI
Lower
Upper
Lymphovascular invasion
0.01
1.80
1.15
2.8
Node positive rate
0.14
1.36
0.90
2.1
Stage
0.49
0.71
0.34
1.5
Table 3 Overall survival according to patterns of recurrence in T4bN1-3M0/TxN3bM0 gastric cancer patients after curative resection
Recurrent sites
Recurrent patients (n = 147)
Median OS (mo)
5-yr OS(%)
P value
n
%
Locoregional
33
22.5%
33.9
28.0%
0.001
Peritoneal
38
25.9%
16.0
0.0%
Distant
67
45.6%
21.3
14.7%
Table 4 Overall survival of patients with T4bN1-3M0/TxN3bM0 gastric cancer according to distant site of metastasis
Distant metastasis site
Recurrent patients (n = 147)
Median OS (mo)
5-yr OS(%)
n
%
Liver
26
17.7%
18.3
15.5%
Lung and pleura
12
8.2%
16.8
0.0%
Bone
10
6.8%
30.7
29.2%
Table 5 Relationship between adjuvant treatment and the prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients
Treatment
n
Median DFS (mo)
3-yr DFS (%)
P value
MedianOS (mo)
5-yr OS (%)
P value
Adjuvant chemotherapy
Yes
164
12.3
10.4%
0.000
25.7
16.1%
0.532
No
12
2.8
0.0%
18.7
22.2%
Chemotherapy
Mono- therapy
10
6.7
0.0%
0.583
20.3
0.0%
0.661
Regimen
Doublet
134
12.0
5.3%
26.3
17.4%
Triple
20
13.0
5.3%
29.7
18.5%
Adjuvant chemotherapy time
≥ 6 mo
39
23.2
20.2%
0.000
40.2
25.0%
0.001
< 6 mo
125
9.9
7.3%
21.6
13.4%
Citation: Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018; 10(1): 31-39